2023年4月22日

补充疗法GmbH (CTx) -生物技术公司开发新的疗法临床前阶段complement-mediated疾病——宣布完成€7200万系列融资。这一轮融资是由Gimv Belgian-based私人股本和风险资本基金共同Forbion作为现有投资者,进一步加入了BioGeneration企业(BGV) Panakes伙伴,剑桥创新资本(CIC),阴间的企业和Seroba生命科学。CTx是曼彻斯特大学的分离出来的初始资金BGV随后在2021年和2022年2月在种子资金筹集了500万€Forbion和BGV。一轮融资,CTx拥有先进CTx001通过临床前概念和获得了一个创新的护照从药物和保健产品监管署(MHRA),并启动non-interventional自然历史研究在英国(我获得)。我获得的研究结果将有助于支持CTx001临床发展规划。最近FDA批准的第一个intravitreal治疗遗传算法GA患者来说是一个重要的里程碑和视网膜社区,进一步验证补充系统的关键作用在遗传算法的开发和发展同时强调针对补充作为治疗策略的重要性。小说和CTx001基因治疗的作用机制有潜力提供卓越的功效比竞争药物和降低治疗患者经过一晚的负担的方法,从而改变治疗景观。除了资金,迈克尔Vlemmix (Gimv),抢劫樵夫(Panakes),安妮•霍根(CIC)和罗杰·富兰克林(阴间的合资企业)将加入董事会新成员。资金将用于:新的一轮融资,CTx将继续发展和完成一个阶段Ib临床证明其铅产品CTx001的概念。和CTx001高度创新AAV基因疗法治疗Geograpic萎缩(GA)二级干年龄相关性黄斑变性(dry-AMD)。 Plus the proceeds from this financing will be deployed to grow its laboratory-based activities in Stevenage (UK), evaluate CTx’s pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform. KEY QUOTES: “With a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of GA through to the clinic. The support of this broad syndicate enables us to generate additional data demonstrating CTx001’s unique and differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.” — Dr. Rafiq Hasan, CEO and Managing Director at Complement Therapeutics GmbH “We are proud to have been able to build this syndicate and look forward to supporting Complement Therapeutics in its next phase of development. The company and its team combine deep research insights, strong industry background, and a robust understanding of complement-mediated conditions, in particular GA secondary to AMD. These strengths, coupled with a focus on addressing the significant unmet need in GA, positions the company to change the way the disease is addressed and potentially achieve meaningful therapeutic impact.” — Michaël Vlemmix, Principal in the Life Sciences platform of Gimv “We are delighted with the rapid progress made by Complement Therapeutics in the last 12 months. Patients impacted by complement-mediated diseases often have to cope with debilitating symptoms throughout their lifetime and this can lead to a significant burden on them and their families. We look forward to supporting the Company as it drives forward a pipeline of novel assets addressing these unmet needs in complement-mediated diseases.” — Dr. Dmitrij Hristodorov, Partner, Forbion Trending on Pulse 2.0